Despite the array of therapies employed in the clinical management of ALI, including glucocorticoids such as dexamethasone [10], neutrophil elastase inhibitors [11], granulocyte-macrophage stimulator (GM-CSF) [12], statin drugs [13] and inhaled nitric oxide [14], their ability to inhibit pro-inflammatory mediators has been limited. Here, ELANE is linked to acute respiratory distress syndrome.